## UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION	)	3:16-md-02750-BRM-LHG
	) ) ) 	JUDGE BRIAN R. MARTINOTTI JUDGE LOIS H. GOODMAN

### THIS DOCUMENT RELATES TO: ALL CASES

#### ADMINISTRATIVE ORDER NO. 2

This matter having been resolved, in part, through the efforts of all parties; the Court having entered Administrative Order No. 1 on 16 August 2018 (ECF No. 270); counsel and the parties having substantially complied with the terms therein; the vast majority of the matters having been resolved and/or dismissed; counsel appearing for a status review and case management conference on April 3, 2019; the Court having considered the submissions, having conferenced with the parties, for good cause and the reasons set forth on the record,

**IT IS** on this 3rd day of April 2019,

**ORDERED** that:

#### I. GENERAL

A. The litigants shall remain categorized into "Existing Plaintiff(s)" and "New Plaintiff(s)" as set forth in Administrative Order No. 1 (ECF No. 270) and shall

<sup>&</sup>lt;sup>1</sup> Defined as plaintiffs with claims pending in MDL Docket No. 2750 prior to August 16, 2018 who have not yet resolved their claims

<sup>&</sup>lt;sup>2</sup> Defined as plaintiffs who file new complaints on or after August 16, 2018 alleging injury resulting from the use of Invokana, whether the case is filed directly in this Court pursuant to the

- continue to respond and produce information regarding their claims accordingly, as directed in that Order.
- B. The Court hereby appoints the Honorable David R. Herndon, U.S.D.J. (ret.) as a Special Master to address any issues relating to the common benefit order. Co-lead counsel shall contact Judge Herndon.

### II. MEMBER CASE DELIQUENCIES

- A. Mitchell Greenbaum, D.O., et al. v. Janssen Pharmaceuticals, Inc., et al., Case No. 3:18-cv-14993
  - 1. The Court finds notice pursuant to Section II.C was provided to Plaintiffs' counsel on January 25, 2019 to comply with Administrative Order No. 1, Sections III.B.(1)-(6) requiring production of discovery to Defendants by December 31, 2018. The 30-day cure period expired on February 24, 2019. As of the date of submission of this proposed agenda, Plaintiffs have failed to provide the following material required under Sections III.B: (i) pharmacy records documenting all prescriptions filled by and dispensed to Mr. Greenbaum from the time period of January 1, 2012 to the present; (ii) an affidavit signed by Plaintiffs attesting to records requests, collection, and production; (iii) a certification of the injury type claimed by Plaintiffs; and (iv) all medical records relating to Mr. Greenbaum from all healthcare providers from the period of January 1, 2012 to the present. The Court finds Plaintiffs have failed to produce the expert reports required pursuant to Administrative Order No 1, Sections III.B.(7)-(8). Defendants sent Plaintiffs a deficiency notice on this issue on March 21, 2019, and the 30day cure period expires on April 20, 2019.
  - 2. Accordingly, Plaintiff shall **SHOW CAUSE** why his complaint should not be dismissed for failure to prosecute. Plaintiff shall file a written submission of not more than five (5) pages via CM/ECF by April 30, 2019. Failure to show cause or otherwise respond may result in dismissal of the matter with prejudice.

Direct Filing Order ("CMO 4") or removed to or transferred to this MDL after the entry of this Order

# III. CASE MANAGEMENT

A. The next Case Management Conference is scheduled for June 13, 2019, at 11:00 a.m. in the Martin Luther King Building & U.S. Courthouse, 50 Walnut Street, Courtroom PO 01, Newark, NJ 07101. Liaison Counsel to appear at 10:30 a.m. The Court will address issues concerning unresolved claims at that conference.

/s/Brian R. Martinotti

HON. BRIAN R. MARTINOTTI United States District Judge